Fig 1: The Role of TGF-β, FasL, and PDL1 Signaling in RPE Immunomodulation(A) The percentage of dividing CD3+ T cells was analyzed following staining of PBMCs with CFSE, activation and co-cultured for 4 days with RPE cells in the presence or absence of inhibitors of TGF-β signaling.(B and C) The percentage of apoptotic annexin V+/PI− cells was analyzed after activation and co-cultured for 1 day with RPE cells in the presence or absence of inhibitors of FasL signaling (B) or anti-PDL1 blocking antibody (α-PDL) (C); na, non-activated T cells; act, cells activated with anti-CD3/anti-CD28 antibodies; SB, SB-431542; A83, A-83-01; α-TGF-β, anti-TGF-β antibody; DcR, recombinant human DcR3; α-FasL, anti-FasL antibody.Data are presented as means ± SEM of at least 3 independent experiments. ∗p ≤ 0.05; ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001.